Argus Research analyst John Eade downgrades Anheuser-Busch InBev (NYSE:BUD) from Buy to Hold.
ADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics’ Persona Technology for NexSys Plasma Collection System
ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the
